Achilles Therapeutics Net Worth
Achilles Therapeutics Net Worth Breakdown | ACHL |
Achilles Therapeutics Net Worth Analysis
Achilles Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Achilles Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Achilles Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Achilles Therapeutics' net worth analysis. One common approach is to calculate Achilles Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Achilles Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Achilles Therapeutics' net worth. This approach calculates the present value of Achilles Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Achilles Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Achilles Therapeutics' net worth. This involves comparing Achilles Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Achilles Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Achilles Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Achilles Therapeutics' net worth research are outlined below:
Achilles Therapeutics may become a speculative penny stock | |
Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Achilles Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from news.google.com: Achilles Therapeutics receives Nasdaq notice for non-compliance - MSN |
Achilles Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Achilles Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Achilles Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
5th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
5th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Know Achilles Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Achilles Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Achilles Therapeutics PLC backward and forwards among themselves. Achilles Therapeutics' institutional investor refers to the entity that pools money to purchase Achilles Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Two Sigma Investments Llc | 2024-09-30 | 21.2 K | Corsair Capital Management Llc | 2024-09-30 | 20 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 16.4 K | Baader Bank Inc | 2024-09-30 | 14.2 K | Susquehanna International Group, Llp | 2024-09-30 | 12.4 K | Brave Asset Management Inc | 2024-09-30 | 10 K | Rhumbline Advisers | 2024-09-30 | 4.5 K | Arcadia Investment Management Corp | 2024-09-30 | 3 K | Jpmorgan Chase & Co | 2024-09-30 | 137 | Syncona Portfolio Ltd. | 2024-09-30 | 11.1 M | Bml Capital Management Llc | 2024-09-30 | 4.1 M |
Follow Achilles Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 47.84 M.Market Cap |
|
Project Achilles Therapeutics' profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.50) | (0.52) | |
Return On Capital Employed | (0.60) | (0.63) | |
Return On Assets | (0.50) | (0.52) | |
Return On Equity | (0.56) | (0.59) |
When accessing Achilles Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Achilles Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Achilles Therapeutics' profitability and make more informed investment decisions.
Evaluate Achilles Therapeutics' management efficiency
Achilles Therapeutics PLC has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4422) %, meaning that it created substantial loss on money invested by shareholders. Achilles Therapeutics' management efficiency ratios could be used to measure how well Achilles Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.52. The value of Return On Capital Employed is expected to slide to -0.63. At this time, Achilles Therapeutics' Total Current Assets are quite stable compared to the past year. Total Assets is expected to rise to about 225.1 M this year, although the value of Other Current Assets will most likely fall to about 4 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 4.10 | 3.89 | |
Tangible Book Value Per Share | 4.10 | 3.89 | |
Enterprise Value Over EBITDA | 1.17 | 1.23 | |
Price Book Value Ratio | 0.29 | 0.27 | |
Enterprise Value Multiple | 1.17 | 1.23 | |
Price Fair Value | 0.29 | 0.27 | |
Enterprise Value | -105.1 M | -99.8 M |
Examining the leadership quality of Achilles Therapeutics PLC offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Achilles Therapeutics time-series forecasting models is one of many Achilles Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Achilles Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Achilles Therapeutics Earnings per Share Projection vs Actual
Achilles Therapeutics Corporate Management
Sergio Quezada | Founder Officer | Profile | |
Daniel Hood | General Secretary | Profile | |
Tariq Ahmed | Executive People | Profile | |
James Taylor | Chief Officer | Profile | |
Julia Wilson | Head Communications | Profile | |
Lee Stern | Vice Communications | Profile | |
FMEDSCI MD | Founder | Profile |
Already Invested in Achilles Therapeutics PLC?
The danger of trading Achilles Therapeutics PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Achilles Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Achilles Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Achilles Therapeutics PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.